NCI-H2122 [H2122] (ATCC® CRL-5985™) Organism: Homo sapiens, human / Cell Type: lymphoblast / Tissue: lung; derived from metastatic site: pleural effusion / Disease: stage 4, adenocarcinoma; non-small cell lung cancer General Information Characteristics Culture Method Specifications History Documentation Print Email Share Share this product Facebook Twitter Google+ Permits and Restrictions View Permits View Restrictions Organism Homo sapiens, human Tissue lung; derived from metastatic site: pleural effusion Cell Type lymphoblast Product Format frozen Morphology it is normal for CRL-5985 to show a mixed morphology of rounded cells and epithelial cells. This cell line produces moderate to large, viable, loose, grape-like clusters that either loosely adhere to the flask or remain in suspension Culture Properties adherent Biosafety Level 1 Biosafety classification is based on U.S. Public Health Service Guidelines, it is the responsibility of the customer to ensure that their facilities comply with biosafety regulations for their own country. Disease stage 4, adenocarcinoma; non-small cell lung cancer Age 46 years Gender female Ethnicity Caucasian, White Storage Conditions liquid nitrogen vapor phase Derivation The line was established in January 1989 from pleural effusion metastasis of lung. Clinical Data 46 years Caucasian female The patient was a smoker 30 pack year Comments A lymphoblastoid line from the same patient is available as ATCC CRL-5967. Complete Growth Medium The base medium for this cell line is ATCC-formulated RPMI-1640 Medium, ATCC 30-2001. To make the complete growth medium, add the following components to the base medium: fetal bovine serum (ATCC 30-2020) to a final concentration of 10%. Subculturing Remove and discard culture medium. Briefly rinse the cell layer with 0.25% (w/v) Trypsin- 0.53 mM EDTA solution to remove all traces of serum that contains trypsin inhibitor. Add 2.0 to 3.0 mL of Trypsin-EDTA solution to flask and observe cells under an inverted microscope until cell layer is dispersed (usually within 5 to 15 minutes). Note: To avoid clumping do not agitate the cells by hitting or shaking the flask while waiting for the cells to detach. Cells that are difficult to detach may be placed at 37°C to facilitate dispersal. Add 6.0 to 8.0 mL of complete growth medium and aspirate cells by gently pipetting. Add appropriate aliquots of the cell suspension to new culture vessels. Incubate cultures at 37°C. Subcultivation Ratio: A subcultivation ratio of 1:3 to 1:4 is recommended Medium Renewal: Every 2 to 3 days Cryopreservation Freeze medium: Complete growth medium supplemented with 5% (v/v) DMSOStorage temperature: liquid nitrogen vapor phase Culture Conditions Atmosphere: air, 95%; carbon dioxide (CO2), 5% Temperature: 37°C STR Profile Amelogenin: XCSF1PO: 10D13S317: 10D16S539: 9,12D5S818: 11,12D7S820: 8,10THO1: 7,9.3TPOX: 9vWA: 17 Name of Depositor AF Gazdar, JD Minna Year of Origin January, 1989 References NCI-Navy Medical Oncology Branch Cell Line Supplement. J. Cell. Biochem. suppl. 24: 1996. Permits These permits may be required for shipping this product: Customers located in the state of Hawaii will need to contact the Hawaii Department of Agriculture to determine if an Import Permit is required. A copy of the permit or documentation that a permit is not required must be sent to ATCC in advance of shipment. Basic Documentation Product Sheet Certificate of Analysis SDS Restrictions The line is available with the following restrictions: This cell line was deposited at the ATCC by Dr. Adi F. Gazdar and is provided for research purposes only. Neither the cell line nor products derived from it may be sold or used for commercial purposes. Nor can the cells be distributed to third parties for purposes of sale, or producing for sale, cells or their products. The cells are provided as service to the research community. They are provided without warranty of merchantability or fitness for a particular purpose or any other warranty, expressed or implied. Any proposed commercial use of the these cells, or their products, must first be negotiated with the National Cancer Institute (NCI). For further information, please contact NCI’s Technology Transfer Center at NCI_TTC_Contact@mail.nih.gov or by phone at (240)-276-5514. References NCI-Navy Medical Oncology Branch Cell Line Supplement. J. Cell. Biochem. suppl. 24: 1996.